Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160316 | 0.90 | HCRTR2 (0.53) | HCRTR1HCRTR2PTGER4PTGER1HDAC1 | |
| SCHEMBL6158510 | 0.90 | HCRTR1 (0.52) | HCRTR1HCRTR2PTGER4PTGER1SRD5A2 | |
| SCHEMBL6162691 | 0.88 | HCRTR2 (0.48) | HCRTR1HCRTR2PTGER4PTGER1 | |
| SCHEMBL6157789 | 0.88 | HCRTR2 (0.54) | HCRTR1HCRTR2HDAC1HDAC6 | |
| SCHEMBL6157202 | 0.86 | HCRTR1 (0.53) | HCRTR1HCRTR2PTGER4PTGER1FFAR1 | |
| SCHEMBL6159575 | 0.85 | HCRTR1 (0.48) | HCRTR1HCRTR2FFAR1SRD5A2HDAC1 | |
| SCHEMBL6162062 | 0.85 | HCRTR1 (0.56) | HCRTR1HCRTR2HDAC1HDAC6 | |
| SCHEMBL6159092 | 0.84 | HCRTR1 (0.51) | HCRTR1HCRTR2PTGER4PTGER1FFAR1 | |
| SCHEMBL6159008 | 0.84 | HCRTR1 (0.55) | HCRTR1HCRTR2FFAR1SRD5A2HDAC1 | |
| SCHEMBL6158757 | 0.83 | EGLN1 (0.49) | HCRTR1HCRTR2HDAC1HDAC6EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953789-B2 | Thiol compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-10-11 | — | — | US | disclosed |
| US-20040157894-A1 | Thiol compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| US-6420415-B1 | Thiol compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1132379-A1 | NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157894-A1 | Thiol compounds, their production and use | TST, SULT1E1, QSOX1 | HCRTR1 1930/4885HCRTR2 1754/4885PTGER4 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.